Anthracite Investment Company Inc. Boosts Stake in Grifols, S.A. (NASDAQ:GRFS)

Anthracite Investment Company Inc. increased its stake in Grifols, S.A. (NASDAQ:GRFS) by 7.4% in the 4th quarter, Holdings Channel reports. The fund owned 659,964 shares of the biotechnology company’s stock after buying an additional 45,410 shares during the quarter. Grifols comprises about 1.7% of Anthracite Investment Company Inc.’s holdings, making the stock its 11th largest position. Anthracite Investment Company Inc.’s holdings in Grifols were worth $4,910,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Financial Engines Advisors L.L.C. purchased a new position in shares of Grifols during the 4th quarter valued at about $358,000. LPL Financial LLC raised its stake in shares of Grifols by 25.0% during the fourth quarter. LPL Financial LLC now owns 75,398 shares of the biotechnology company’s stock worth $561,000 after acquiring an additional 15,067 shares in the last quarter. Chesapeake Capital Corp IL lifted its holdings in shares of Grifols by 49.3% in the 4th quarter. Chesapeake Capital Corp IL now owns 24,638 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 8,138 shares during the last quarter. Corient Private Wealth LLC boosted its stake in shares of Grifols by 11.0% in the 4th quarter. Corient Private Wealth LLC now owns 50,883 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 5,040 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. purchased a new stake in shares of Grifols in the 4th quarter valued at $77,000.

Grifols Trading Down 2.6 %

Shares of GRFS stock opened at $7.55 on Wednesday. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The business has a 50-day moving average of $7.56 and a 200 day moving average of $8.07. The stock has a market capitalization of $5.19 billion, a PE ratio of 6.45 and a beta of 0.35. Grifols, S.A. has a 1-year low of $5.79 and a 1-year high of $9.96.

Wall Street Analyst Weigh In

Separately, Morgan Stanley started coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating for the company.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.